Navigation Links
Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
Date:5/1/2012

e of our key pharmaceutical products," said Dave Holveck, president and CEO of Endo. "We are keenly focused on execution that creates the opportunity for us to continue to grow our products and services and execute our long-term vision of providing our customers with innovative healthcare solutions."

Reported diluted loss per share includes the impact of a pre-tax charge in the amount of $110 million for the period to reflect a one-time payment that the company now expects to make to Impax per the terms of Endo's 2010 settlement and license agreement with Impax.  The company recognized a liability under this agreement upon successfully demonstrating, in response to the Novartis supply disruption, the ability to accelerate the manufacture and sale of the new formulation of OPANA ER, which occurred in March 2012. 

FINANCIAL PERFORMANCE AT A GLANCE1st Quarter20122011ChangeTotal Revenues$690,633

$560,026

23%Reported Net (Loss) Income(87,345)

55,787

NMReported Diluted (Loss) Income per share(0.75)

0.46

NMAdjusted Net Income106,300

120,178

(12)%Adjusted Diluted EPS$0.87

$1.00

(13)%OPANA ER AND VOLTAREN GEL SUPPLY UPDATEEndo also announced that it has now returned to steady supply of the new formulation of OPANA ER (oxymorphone HCL) designed to be crush-resistant and Voltaren Gel (diclofenac sodium topical gel) 1%.  The company believes there is adequate product available for all appropriate patients, both existing and new starts, following a short-term supply disruption announced in early January.

"We are pleased to have these two important products back in steady supply across the country," said Julie McHugh, chief operating officer at Endo. "Endo's top priority is the health, well-being, and the continuity of care for our patients. Now that there is better accessibility to OPANA ER and Voltaren Gel, physicians should feel confident in prescrib
'/>"/>

SOURCE Endo
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Hospira Reports First-Quarter 2012 Results
2. Luminex Corporation Reports First Quarter 2012 Results
3. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
4. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Cepheid Reports 2012 First Quarter Results
11. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... MONTVALE, N.J., Feb. 19 Memory,Pharmaceuticals Corp. ... plans to,conduct a clinical study of MEM 3454, ... biomarkers of schizophrenia, P50 sensory gating and,mismatch negativity, ... formulation and manufacturing activities for MEM 3454, will,be ...
... seven-year, international,study published today finds that some alternative ... better choices for managing,most common neck pain than ... best options for relief are exercises, education, neck,mobilization, ... Therapies such as neck collars and ultrasound are ...
Cached Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Seven-Year Neck Pain Study Sheds Light on Best Care 2Seven-Year Neck Pain Study Sheds Light on Best Care 3
(Date:5/19/2013)... Healthcare leaders will gather at the ... Walt Disney World Swan and Dolphin in Orlando, Fla., ... care delivery and healthcare reform and implementation. , “Reform ... markets, with consolidation, efficiency and reduced payments ... Ebert, Amerinet president and CEO. “There is a real ...
(Date:5/19/2013)... 19, 2013 The muscles in the ... functionality and one of the biggest and most significant ... system. The peripheral system comprises of peripheral nerves that ... These nerves ensure that the limbs and hands, as ... these nerves get damaged due to trauma or physical ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Agora Health Limited ... that covers guides on how to increase memory power ... memory training method that helps people re-new their entire health ... and beat depression caused by a fatigued mind. In addition, ... razor sharp for a lifetime. The author claimed that this ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
... Food Experts HARRY EASTWOOD, ALLISON FISHMAN ... Tiger Aspect Productions Lose the Bulge...but Still ... to have your cake and eat it, too? Lifetime ... that offers viewers the skills and the confidence to give ...
... Lincoln Financial Group (NYSE: LNC ) today ... on its group long-term disability (LTD) insurance product. Lincoln already ... market and -- with the addition of this optional benefit ... insureds overcome family care cost concerns as they try to ...
... REDUCED ETS EXPOSURE , Environmental tobacco smoke (ETS) ... children. However, a new study shows that reducing ... of Alabama researchers followed 240 children with asthma ... asthma therapy. No smoking cessation counseling or ETS ...
... County Health Authority has begun using a web-based ... and enrollment of prospective Medicaid recipients. The new ... health care technology firm based in Norwalk, CT. ... patients to the right assistance program by facilitating ...
... 7 MedPage Today , the only breaking medical ... the challenge posed by the downsizing of newspapers and other ... Today is not only standing firm, but is investigating ... C.E.O. of MedPage Today . The full pledge is ...
Cached Medicine News:Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 2Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 4Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 2Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 3Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 4Health News:Journal Chest: April news briefs 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:MedPage Today Pledges to Maintain and Expand News Coverage in 2009 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: